C4 Therapeutics, Inc.
CCCC
$1.54
$0.042.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.18M | 15.36M | 12.01M | 3.04M | 3.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.18M | 15.36M | 12.01M | 3.04M | 3.26M |
| Cost of Revenue | 32.51M | 31.84M | 23.75M | 22.53M | 30.39M |
| Gross Profit | -27.34M | -16.48M | -11.75M | -19.49M | -27.13M |
| SG&A Expenses | 10.37M | 11.77M | 9.70M | 10.29M | 10.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.89M | 43.61M | 33.45M | 32.82M | 40.69M |
| Operating Income | -37.71M | -28.24M | -21.44M | -29.78M | -37.43M |
| Income Before Tax | -34.44M | -24.67M | -17.72M | -28.36M | -34.48M |
| Income Tax Expenses | 131.00K | -- | -- | -- | 277.00K |
| Earnings from Continuing Operations | -34.57M | -24.67M | -17.72M | -28.36M | -34.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.57M | -24.67M | -17.72M | -28.36M | -34.75M |
| EBIT | -37.71M | -28.24M | -21.44M | -29.78M | -37.43M |
| EBITDA | -37.23M | -27.80M | -20.99M | -29.33M | -37.00M |
| EPS Basic | -0.49 | -0.35 | -0.26 | -0.41 | -0.68 |
| Normalized Basic EPS | -0.31 | -0.22 | -0.19 | -0.24 | -0.43 |
| EPS Diluted | -0.49 | -0.35 | -0.26 | -0.41 | -0.68 |
| Normalized Diluted EPS | -0.31 | -0.22 | -0.19 | -0.24 | -0.43 |
| Average Basic Shares Outstanding | 70.61M | 69.63M | 68.81M | 68.43M | 51.25M |
| Average Diluted Shares Outstanding | 70.61M | 69.63M | 68.81M | 68.43M | 51.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |